Surprisingly high costs, but solid top-line and customer intake We cut '25e EBITA by 7%, but raise '...
Redeye strengthens its positive view of CombinedX following a solid Q1, considering the soft market,...
Problemen i Storbritannien och uppskalningen av organisationen tynger resultaten tillfälligt, men an...
Report out 14 May at 07:45 CEST Pome sale the largest Q1 contributor, Stor-Skälsjön completed Q1e EB...
Redeye comments on Avensia’s Q1 report, beating our expectations significantly on both sales and EBI...
Redeye comments on the Q1 sales for Leqembi and shortly on our expectations ahead of the report.
Inledningen av 2025 var i linje med våra förväntningar.
JonDeTechs första kvartal 2025 präglades av sju nya aktiva kundprojekt där det tidigare aviserade pr...
Sales trough reached, return to EBIT growth in Q3e '25e-'27e EBIT down 29-13% on FX and system sales...
Organic growth 33% y-o-y; adj. EBITA 44% vs ABGSCe Beat in low season quarter, but est's +3-5% Posit...
Redeye provides an initial comment on the Q1 2025 report from Cheffelo, which was in line with annou...
Redeye comments on W5’s Q1-results which were softer than expected while the order intake remained s...
Investors House reported Q1 revenues of EUR 2.7m, 4% below our estimate.
Back to wallpaper growth in Q1 We lower '25e-'26e EBITA by 2-3% on Artscape-driven Q1 miss We reiter...
Nanexa continues to strengthen the foundation for the upcoming Phase Ib/II study in the NEX-22 proje...
Redeye comments on G5’s Q1-results which saw a weaker topline than expected and while reported EBIT ...
Redeye updates its estimates following Freemelt’s Q1 report, which came in lower than expected in te...
We downgrade our 2025-27 sales estimates by ~8%, owing to FX, while we downgrade 2025E-27E adjusted ...
Redeye updates its estimates and fair value range following CTEK’s Q1 results, which exceeded our ex...
Acconeer's first quarter 2025 net sales growth of 20% y/y (or -12% adjusted for the postponed order)...